Loading
NASDAQHealthcareBiotechnology
Latest quote
$30.545
+$0.545 · +1.82%
IRulya Therapeutics is a clinical-stage biopharmaceutical company developing LAM-001, an inhaled formulation of rapamycin, for pulmonary diseases. Its clinical programs target pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome after lung transplant, and sarcoidosis-associated pulmonary hypertension.
Regular session
$30.545
+$0.545 · +1.82%
Regular session · ET · Market data may be delayed.
IRulya Therapeutics is a clinical-stage biopharmaceutical company developing LAM-001, an inhaled formulation of rapamycin, for pulmonary diseases. Its clinical programs target pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome after lung transplant, and sarcoidosis-associated pulmonary hypertension.
Day range
Current $30.545
52-week range
Current $30.545
Regular session · ET · Market data may be delayed.
IRulya Therapeutics is a clinical-stage biopharmaceutical company developing LAM-001, an inhaled formulation of rapamycin, for pulmonary diseases. Its clinical programs target pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome after lung transplant, and sarcoidosis-associated pulmonary hypertension.
Day range
Current $30.545
52-week range
Current $30.545
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 142K USD | — | — | — | — |
| Gross profit | −142K USD | — | — | — | — |
| Research and development | 35.38M USD | 18.59M USD | 9.45M USD | 25.18M USD | 60.8M USD |
| Selling, general, and administrative | 15.05M USD | 17.58M USD | 17.7M USD | 26.01M USD | 29.52M USD |
| Operating expenses | 50.29M USD | 57.29M USD | 34.62M USD | 52.02M USD | 90.32M USD |
| Interest income | 1.24M USD | 2.93M USD | 3.48M USD | 1.07M USD | 620K USD |
| Interest expense | — | — | — | 568K USD | — |
| Depreciation and amortization | 142K USD | 186K USD | 322K USD | 204K USD | 344K USD |
| Operating income | −50.43M USD | −57.29M USD | −34.62M USD | −52.02M USD | −90.32M USD |
| Net income | −83.98M USD | −56.83M USD | −31.39M USD | −51.66M USD | −89.95M USD |
Company facts updated Oct 15, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
